Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IDRA - Idera Pharmaceuticals, Inc.


Close
0.425
-0.117   -27.506%

Share volume: 0
Last Updated: Tue 17 Jan 2023 10:00:01 PM CET
Biological Product (except Diagnostic) Manufacturing : -3.41%

PREVIOUS CLOSE
CHG
CHG%

$0.54
-0.12
-21.57%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
34%
Profitability 40%
Dept financing 25%
Liquidity 38%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-8.17%
1 Month
57.41%
3 Months
20.81%
6 Months
-1.46%
1 Year
-35.03%
2 Year
-90.51%
Key data
Stock price
$0.42
P/E Ratio 
-0.30
DAY RANGE
N/A - N/A
EPS 
-$2.67
52 WEEK RANGE
$0.22 - $0.79
52 WEEK CHANGE
-$0.36
MARKET CAP 
26.501 M
YIELD 
N/A
SHARES OUTSTANDING 
62.355 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.66
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$328,032
AVERAGE 30 VOLUME 
$325,737
Company detail
CEO: Vincent Milano
Region: US
Website: www.iderapharma.com
Employees: 32
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Recent news